AstraZeneca PLC (AZN) — closed signal from December 3, 2025
Target reached Published before the outcome was known, scored automatically when the window closed on March 3, 2026.
Predicted vs. what happened
AZN price · publication thesis → realized outcomesplit-adjusted
$344.71 – $360.38Entry zone — fair-value band
$179.33Published — price the day we called it
$418.82Target — the price the thesis aimed for
$210.50Peak — highest point inside the window, not a realized return
$201.76Window close — end-of-window price, context only
What happened
Target reached
Hit or exceeded the predicted growth inside the window.
Peak price
$210.50
peak on February 18, 2026 — not a realized returnPeak gain
+17.4%
peak, from the publication priceWindow close
$201.76
end-of-window price, context onlyDays to target
—
Window
December 3, 2025 – March 3, 2026
The thesis — published December 3, 2025
Predicted growth
+18%
over the measurement windowTarget price
$418.82
the price the thesis aimed forEntry zone
$344.71 – $360.38
the fair-value band we waited forPrice at publication
$179.33
published December 3, 2025Confidence
78%
how strongly the data lined upTimeframe
Short-term (0–3 months)
AstraZeneca looks like a high-quality large drug company that has fallen enough to invite buyers. Signs that selling has slowed and early price improvement make a rebound likely. A major bank named it a top pick and raised its price target to 108.50. New AI pathology work also strengthens the story and improves short-term sentiment.
Primary drivers
- Stock fell a lot and now shows signs selling may be ending.
- A top bank picked AZN for 2026 and raised its price target.
- AI tools for pathology strengthen the company's drug development story.
- Pharma's defensive nature helps if markets turn down.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Lyra
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.